Aristopharma Ltd. has launched Arixatin concentrated solution for IV infusion, for colorectal and advanced colon cancers.
Arixatin contains oxaliplatin, a third-generation platinum chemotherapeutic used mainly in colorectal cancer. It forms reactive platinum species that create DNA crosslinks (particularly at guanine N7) in cancer cells, thereby blocking DNA replication/transcription and causing cell-cycle–nonspecific cytotoxicity. In practice, oxaliplatin is given intravenously (no oral absorption) in combination regimens. Its key uses are adjuvant therapy for stage III (resected) colon cancer and first-line therapy for advanced (metastatic) colorectal cancer. In current practice, FOLFOX (oxaliplatin + 5-FU/LV) or CAPOX/XELOX (oxaliplatin + oral capecitabine) are standard regimens. Arixatin is available as a 50 mg and 100 mg concentrated solution for IV infusion. The 100 mg pack will be provided with a complimentary infusion set for patient convenience.
FR
DE